Arcus Biosciences, Inc. (RCUS) Debt Components
- 2026-06-30: Long-term DebtUSD $101.00M; Long-term Debt, GrossUSD $100.00M; Debt Instrument, Interest Rate, Effective Percentagepure (m); Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $-1.00M.
- 2026-03-31: Long-term DebtUSD $100.00M; Long-term Debt, GrossUSD $100.00M; Debt Instrument, Interest Rate, Effective Percentagepure (m); Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $0.00.
- 2025-12-31: Long-term DebtUSD $99.00M; Long-term Debt, GrossUSD $100.00M; Debt Instrument, Interest Rate, Effective Percentagepure 12.85%; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $1.00M.
- 2025-09-30: Long-term DebtUSD $98.00M; Long-term Debt, GrossUSD $100.00M; Debt Instrument, Interest Rate, Effective Percentagepure 13.08%; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $2.00M.
Arcus Biosciences, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Long-term Debt, Gross USD | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|
| 2026-06-30 | $101.00M | $100.00M | (m) | $-1.00M |
| 2026-03-31 | $100.00M | $100.00M | (m) | $0.00 |
| 2025-12-31 | $99.00M | $100.00M | 12.85% | $1.00M |
| 2025-09-30 | $98.00M | $100.00M | 13.08% | $2.00M |
| 2025-06-30 | (m) | (m) | 13.08% | (m) |
| 2025-06-30 | $97.00M | $100.00M | (m) | $3.00M |
| 2025-03-31 | (m) | (m) | 13.39% | (m) |
| 2025-03-31 | $48.00M | $50.00M | (m) | $2.00M |
| 2024-12-31 | $48.00M | $50.00M | (m) | $2.00M |
| 2024-12-31 | (m) | (m) | 13.39% | (m) |
| 2024-09-30 | $47.00M | $50.00M | 13.39% | $3.00M |
| 2023-12-31 | $0.00 | $0.00 | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |